Literature DB >> 35551655

Development of Cancer Immunotherapies.

Diana C DeLucia1, John K Lee2.   

Abstract

Cancer immunotherapy, or the utilization of components of the immune system to target and eliminate cancer, has become a highly active area of research in the past several decades and a common treatment strategy for several cancer types. The concept of harnessing the immune system for this purpose originated over 100 years ago when a physician by the name of William Coley successfully treated several of his cancer patients with a combination of live and attenuated bacteria, later known as "Coley's Toxins", after observing a subset of prior patients enter remission following their diagnosis with the common bacterial infection, erysipelas. However, it was not until late in the twentieth century that cancer immunotherapies were developed for widespread use, thereby transforming the treatment landscape of numerous cancer types. Pivotal studies elucidating molecular and cellular functions of immune cells, such as the discovery of IL-2 and production of monoclonal antibodies, fostered the development of novel techniques for studying the immune system and ultimately the development and approval of several cancer immunotherapies by the United States Food and Drug Association in the 1980s and 1990s, including the tuberculosis vaccine-Bacillus Calmette-Guérin, IL-2, and the CD20-targeting monoclonal antibody. Approval of the first therapeutic cancer vaccine, Sipuleucel-T, for the treatment of metastatic castration-resistant prostate cancer and the groundbreaking success and approval of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy in the last decade, have driven an explosion of interest in and pursuit of novel cancer immunotherapy strategies. A broad range of modalities ranging from antibodies to adoptive T cell therapies is under investigation for the generalized treatment of a broad spectrum of cancers as well as personalized medicine. This chapter will focus on the recent advances, current strategies, and future outlook of immunotherapy development for the treatment of cancer.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Active cancer immunotherapy; Antibodies; Cancer vaccines; Immune checkpoint inhibition; Passive cancer immunotherapy; T cell therapies

Mesh:

Substances:

Year:  2022        PMID: 35551655     DOI: 10.1007/978-3-030-96376-7_1

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  263 in total

Review 1.  IMMUNOLOGY OF EXPERIMENTAL TUMORS.

Authors:  L J OLD; E A BOYSE
Journal:  Annu Rev Med       Date:  1964       Impact factor: 13.739

Review 2.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

Review 3.  Tumors of the immunocompromised patient.

Authors:  I Penn
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739

4.  Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited.

Authors:  William K Decker; Amar Safdar
Journal:  Cytokine Growth Factor Rev       Date:  2009-08-04       Impact factor: 7.638

5.  Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience.

Authors:  Sabine Roithmaier; Andrew M Haydon; Sherene Loi; Don Esmore; Ann Griffiths; Peter Bergin; Trevor J Williams; Max A Schwarz
Journal:  J Heart Lung Transplant       Date:  2007-08       Impact factor: 10.247

Review 6.  Epithelial Mesenchymal Transition in Tumor Metastasis.

Authors:  Vivek Mittal
Journal:  Annu Rev Pathol       Date:  2018-01-24       Impact factor: 23.472

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 8.  Innate immunity: ignored for decades, but not forgotten.

Authors:  Robert L Modlin
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

9.  EMT in immuno-resistance.

Authors:  Stéphane Terry; Salem Chouaib
Journal:  Oncoscience       Date:  2015-08-31

Review 10.  From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review).

Authors:  Volker Schirrmacher
Journal:  Int J Oncol       Date:  2018-12-10       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.